Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities

References

• Zingone A, Kuehl WM. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol 2011;48:4–12.
   PubMed Web of Science ®Google Scholar
• Van Riet I, De Waele M, Remels L, et al. Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells. Br J Haematol 1991;79:421–427.
   PubMed Web of Science ®Google Scholar
• Mateo G, Montalban MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008;26:2737–2744.
   PubMed Web of Science ®Google Scholar
• Bataille R, Jego G, Robillard N, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy. Haematologica 2006;91:1234–1240.
   PubMed Web of Science ®Google Scholar
• Kumar S, Kimlinger T, Morice W, et al. Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol 2010;23:433–451.
   PubMed Web of Science ®Google Scholar
• Raja KR, Kovarova L, Hajek R, et al. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010;149:334–351.
   PubMed Web of Science ®Google Scholar
• Singh C, Yohe S, Baughn L, et al. Utility of flow ctyometry to classify abnormal plasma cell populations in marrow samples collected from patients with putative plasma cell neoplasms. Open J Blood Dis 2012;2:39–45.
   Google Scholar
• Mateo G, Castellanos M, Rasillo A, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005;11:3661–3667.
   PubMed Web of Science ®Google Scholar
• Kastrinakis NG, Gorgoulis VG, Foukas PG, et al. Molecular aspects of multiple myeloma. Ann Oncol 2000;11:1217–1228.
   PubMed Web of Science ®Google Scholar
• Debes-Marun CS, Dewald GW, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003;17:427–436.
   PubMed Web of Science ®Google Scholar
• Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 2011; 204:3–12.
   PubMed Web of Science ®Google Scholar
• Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745–1757.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi X, Jiang A, et al. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 2010; 45:117–121.
   PubMed Web of Science ®Google Scholar
• Shi L, Wang S, Zangari M, et al. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 2010;1:22–33.
   PubMedGoogle Scholar
• Shetty S, Siady M, Mallempati KC, et al. Utility of a column- free cell sorting system for separation of plasma cells in multiple myeloma FISH testing in clinical laboratories. Int J Hematol 2012; 95:274–281.
   PubMed Web of Science ®Google Scholar
• Quinn J, Percy L, Glassford J, et al. CD20-positive multiple myeloma - differential expression of cyclins D1 and D2 suggests a heterogeneous disease. Br J Haematol 2010;149:156–159.
   PubMed Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020–2028.
   PubMed Web of Science ®Google Scholar
• Xiong W, Wu X, Starnes S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008;112:4235–4246.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of Total Therapy 3. Br J Haematol 2007;138:176–185.
   PubMed Web of Science ®Google Scholar
• Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531–537.
   PubMed Web of Science ®Google Scholar
• Zhan F, Barlogie B, Arzoumanian V, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007;109:1692–1700.
   PubMed Web of Science ®Google Scholar
• Pozdnyakova O, Morgan EA, Li B, et al. Patterns of expression of CD56 and CD117 on neoplastic plasma cells and association with genetically distinct subtypes of plasma cell myeloma. Leuk Lymphoma 2012;53:1905–1910.
   PubMed Web of Science ®Google Scholar